

BIOCRYST PHARMACEUTICALS INC

Form 8-K

February 08, 2006

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: February 8, 2006**

**BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**000-23186**  
(Commission File Number)

**62-1413174**  
(IRS Employer Identification #)

**2190 Parkway Lake Drive, Birmingham, Alabama 35244**

(Address of Principal Executive Office)

**(205) 444-4600**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02. Results of Operations and Financial Condition:**

On February 8, 2006, the Company issued a news release announcing its financial results for the quarter and year ended December 31, 2005, which also referenced a conference call to discuss these results and provide an update on the status of the Company's programs. A copy of the news release is furnished as exhibit 99.1 hereto and is incorporated by reference into Item 9.01 of Form 8-K.

**Item 9.01. Financial Statements and Exhibits:**

Exhibit No.	Description
99.1	Press release dated February 8, 2006 entitled BioCryst Reports Fourth Quarter and Year-End 2005 Financial Results .

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 8, 2006

BioCryst Pharmaceuticals, Inc.

By: /s/ Michael A. Darwin

---

Michael A. Darwin  
Chief Financial Officer and Chief  
Accounting Officer

**EXHIBIT INDEX**

<b>Item</b>	<b>Description</b>
99.1	Press release dated February 8, 2006 entitled BioCryst Reports Fourth Quarter and Year-End 2005 Financial Results .